ACADIA Pharmaceuticals Inc represents values of innovation, excellence, and compassion in the pharmaceutical industry. The company's corporate philosophy revolves around developing breakthrough therapies that address unmet medical needs, with a particular focus on neurological and central nervous system disorders. ACADIA Pharmaceuticals Inc aims to improve patients' lives by delivering novel treatments and advancing scientific understanding. With a commitment to rigorous research, collaboration, and patient-centricity, the company strives to make a meaningful impact in healthcare. ACADIA Pharmaceuticals Inc embraces a culture of continuous learning, growth, and ethical practices to drive positive change and bring hope to those in need.

ACADIA Pharmaceuticals Inc is primarily present in the United States.

ACADIA Pharmaceuticals Inc has achieved several significant milestones. The company's groundbreaking drug, pimavanserin, received FDA approval in 2016 for the treatment of Parkinson's disease psychosis (PDP). This made ACADIA the first and only pharmaceutical company with an FDA-approved treatment for this condition. In 2020, ACADIA also received FDA approval for pimavanserin as a treatment for hallucinations and delusions associated with dementia-related psychosis (DRP). These approvals have not only established ACADIA as a leader in the field of neurological therapeutics but also provided hope and improved quality of life for patients suffering from debilitating psychotic symptoms.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative medicines to address unmet medical needs. Founded in 1997, ACADIA has been dedicated to advancing breakthrough therapies for central nervous system disorders. The company focuses on researching and developing small molecule drugs that target specific neurotransmitter receptors in the brain. ACADIA is recognized for its leading drug, Nuplazid, which is approved for the treatment of Parkinson's disease psychosis. Committed to improving patients' lives, ACADIA strives to drive scientific advancements and create value for healthcare providers and stakeholders in the pharmaceutical industry.

The main competitors of ACADIA Pharmaceuticals Inc in the market are Biogen Inc., AbbVie Inc., and Johnson & Johnson.

ACADIA Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

The business model of ACADIA Pharmaceuticals Inc revolves around the research, development, and commercialization of innovative therapies for central nervous system disorders. With a focus on neurology and psychiatry, ACADIA develops and markets drugs that aim to improve the lives of patients suffering from neurological and psychiatric conditions such as Parkinson's disease, schizophrenia, and Alzheimer's disease. Through strategic collaborations, clinical trials, and regulatory approvals, ACADIA aims to bring transformative therapies to market, addressing unmet medical needs in the field of central nervous system disorders. ACADIA Pharmaceuticals Inc continuously strives to enhance patient outcomes and maximize shareholder value through its dedicated efforts in drug development and commercialization.

ACADIA Pharmaceuticals KGV ir 32,34.

ACADIA Pharmaceuticals KUV ir 3,20.

AlleAktien kvalitātes vērtējums ACADIA Pharmaceuticals ir 6/10.

gaidāmā ACADIA Pharmaceuticals apgrozījums ir 972,66 milj. USD.

gaidāmā ACADIA Pharmaceuticals peļņa ir 96,33 milj. USD.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The company is headquartered in San Diego, California, USA. ACADIA Pharmaceuticals is divided into two divisions: clinical development and commercial marketing. In clinical development, the company is working on developing new drugs for the treatment of CNS disorders such as Parkinson's disease, Alzheimer's disease, depressive disorders, and schizophrenia. The goal is to help patients reduce their symptoms and improve their quality of life. The commercial division is responsible for bringing to market and distributing the medication developed by ACADIA Pharmaceuticals. In 2020, the company successfully entered the market with the medication Nuplazid, which is used to treat hallucinations and delusions in patients with Parkinson's disease. ACADIA Pharmaceuticals' business model is based on the development of drugs for the treatment of CNS disorders. The company uses a proprietary chemical technology platform that enables the identification and optimization of novel compounds. An important component of ACADIA Pharmaceuticals' business model is its focus on partnerships with other companies and institutions. By collaborating with other pharmaceutical companies, ACADIA Pharmaceuticals can access a wider network of resources and expertise to accelerate the development of new medications and reduce costs. The company also works closely with academic research institutions to advance the research and development of new compounds. In 2020, ACADIA Pharmaceuticals generated approximately $1.1 billion in revenue. The company employs approximately 1,500 people worldwide and has marketed its products in over 20 countries. ACADIA Pharmaceuticals is listed on the NASDAQ stock exchange under the symbol ACAD. In summary, ACADIA Pharmaceuticals' business model is based on the development and commercialization of innovative therapies for CNS disorders. The company utilizes a proprietary technology platform and collaborates closely with other companies and research institutions to accelerate the development of new medications. With a successful market entry of Nuplazid in 2020, ACADIA Pharmaceuticals is on track to achieve its goals and further expand its business model.

ACADIA Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt ACADIA Pharmaceuticals vai uzņēmums nedod dividendes.

ACADIA Pharmaceuticals ISIN ir US0042251084.

ACADIA Pharmaceuticals WKN ir 603035.

ACADIA Pharmaceuticals simbols ir ACAD.

Pēdējo 12 mēnešu laikā ACADIA Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos ACADIA Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

ACADIA Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

ACADIA Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

ACADIA Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

ACADIA Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu ACADIA Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 1.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 1.08.2024..

Pēdējās dividendes izmaksa notika 1.08.2024..

Gadā 2023, ACADIA Pharmaceuticals izmaksāja 0 USD dividendes.

ACADIA Pharmaceuticals dividendes tiek izmaksātas USD.